ClinConnect ClinConnect Logo
Search / Trial NCT03364478

Comparative Study of Medial-to-Lateral Approach vs Dorsal and Medial Hybrid Approach in Laparoscopic Right Hemicolectomy

Launched by SHANGHAI MINIMALLY INVASIVE SURGERY CENTER · Dec 1, 2017

Trial Information

Current as of June 13, 2025

Unknown status

Keywords

Surgical Approach Laparoscopic Right Hemicolectomy

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged more then 18 years old;
  • Diagnosed as right hemi colonic cancer with colonoscopic biopsy;
  • Without metastasis;
  • No Invasion of surrounding tissues;
  • Limited operation;
  • Underwent laparoscopic radical right hemicolectomy (L-right hemicolectomy);
  • BMI 18\~30kg/m2;
  • Without multiple primary tumors;
  • Sign on the Medical informed Consent.
  • Exclusion Criteria:
  • Simultaneous or simultaneous multiple primary colorectal cancer;
  • * Preoperative imaging examination results show:
  • 1. Tumor involves the surrounding organs and combined organ resection need to be done;
  • 2. Distant metastasis;
  • 3. Unable to perform R0 resection;
  • History of any other malignant tumor in recent 5 years;
  • Patients need emergency operation;
  • Not suitable for laparoscopic surgery;
  • Women during Pregnancy or breast feeding period;
  • Informed consent refusal

About Shanghai Minimally Invasive Surgery Center

The Shanghai Minimally Invasive Surgery Center is a leading clinical trial sponsor dedicated to advancing the field of minimally invasive surgical techniques through innovative research and development. With a focus on improving patient outcomes and enhancing recovery times, the center collaborates with healthcare professionals and researchers to conduct rigorous clinical trials that evaluate the safety and efficacy of cutting-edge surgical interventions. Committed to upholding the highest ethical standards and regulatory compliance, the Shanghai Minimally Invasive Surgery Center aims to contribute to the global medical community by translating scientific discoveries into practical applications that benefit patients worldwide.

Locations

Shanghai, Sahgnhai, China

Patients applied

0 patients applied

Trial Officials

Minhua Zheng, PhD

Study Director

Ruijin Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials